However, as demonstrated in the recent EORTC trial of Atezolizumab in CTCL, baseline PD-L1 expression did not correlate with response to therapy, suggesting that commonly used biomarkers in melanoma may not reliably predict outcomes in MF [9]. This evidence concerns the gene CD274 and melanoma.